NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis $2.41 -0.10 (-3.98%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.37▼$2.5750-Day Range$2.08▼$3.5052-Week Range$2.01▼$5.78Volume1.10 million shsAverage Volume2.55 million shsMarket Capitalization$503.69 millionP/E RatioN/ADividend YieldN/APrice Target$9.96 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Allogene Therapeutics alerts: Email Address Allogene Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside313.1% Upside$9.96 Price TargetShort InterestBearish28.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.38) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.99 out of 5 starsMedical Sector335th out of 910 stocksBiological Products, Except Diagnostic Industry50th out of 155 stocks 4.4 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAllogene Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Allogene Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.65% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 3.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 3.3 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 17 people have searched for ALLO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.30% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allogene Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.38) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allogene Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Allogene Therapeutics Stock (NASDAQ:ALLO)Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Read More ALLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLO Stock News HeadlinesSeptember 7 at 7:55 AM | 247wallst.com3 Hot Penny Stocks to Buy With $1000September 2, 2024 | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Expected to Post Q3 2024 Earnings of ($0.37) Per ShareSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Allogene Therapeutics on Strong Financials and Positive Pipeline ProspectsAugust 14, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)August 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)August 9, 2024 | markets.businessinsider.comAllogene Therapeutics’ Promising Drug Pipeline and Study Advancements Bolster Buy RatingAugust 9, 2024 | markets.businessinsider.comAllogene Therapeutics’ Promising Drug Pipeline and Study Advancements Bolster Buy RatingSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 9, 2024 | finance.yahoo.comAllogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)August 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Allogene Therapeutics (ALLO)August 8, 2024 | benzinga.comA Closer Look at 6 Analyst Recommendations For Allogene TherapeuticsAugust 8, 2024 | globenewswire.comAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesAugust 7, 2024 | globenewswire.comAllogene Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdateAugust 7, 2024 | markets.businessinsider.comHere's what to expect from Allogene Therapeutics's earningsAugust 6, 2024 | msn.comAxsome Therapeutics (AXSM) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | globenewswire.comAllogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business UpdateJuly 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Ocular Therapeutix (OCUL) and Repare Therapeutics (RPTX)See More Headlines Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees232Year Founded2018Price Target and Rating Average Stock Price Target$9.96 High Stock Price Target$14.00 Low Stock Price Target$4.60 Potential Upside/Downside+313.1%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-327,270,000.00 Net Margins-223,139.98% Pretax Margin-324,910.44% Return on Equity-50.24% Return on Assets-40.21% Debt Debt-to-Equity RatioN/A Current Ratio12.25 Quick Ratio12.25 Sales & Book Value Annual Sales$65,000.00 Price / Sales7,749.08 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.98Miscellaneous Outstanding Shares209,000,000Free Float158,213,000Market Cap$503.69 million OptionableOptionable Beta0.83 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 75)M.D., Co-Founder & Executive Chairman Comp: $649.1kDr. David D. Chang M.D. (Age 64)Ph.D., Co-Founder, President, CEO & Director Comp: $994.6kMr. Joshua A. Kazam (Age 47)Co-Founder & Director Comp: $260.5kMr. Timothy L. Moore Ph.D. (Age 63)Executive VP & Chief Technical Officer Comp: $554.35kDr. Zachary J. Roberts M.D. (Age 46)Ph.D., Executive VP of Research & Development and Chief Medical Officer Comp: $747.39kMr. Geoffrey M. Parker (Age 59)Executive VP & CFO Ms. Annie Yoshiyama (Age 40)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Earl M. Douglas Esq. (Age 61)Senior VP, General Counsel, Compliance Officer & Corporate Secretary Ms. Susan R. Lundeen (Age 58)Chief People Officer Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy OfficerMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUERecursion PharmaceuticalsNASDAQ:RXRXBeam TherapeuticsNASDAQ:BEAMImmunocoreNASDAQ:IMCRNovavaxNASDAQ:NVAXView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 2,725,000 shares on 8/16/2024Ownership: 1.304%Algert Global LLCBought 14,808 shares on 8/16/2024Ownership: 0.007%Caxton Associates LPBought 34,924 shares on 8/15/2024Ownership: 0.223%Susquehanna Fundamental Investments LLCBought 132,291 shares on 8/15/2024Ownership: 0.200%AQR Capital Management LLCBought 27,287 shares on 8/15/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ALLO Stock Analysis - Frequently Asked Questions How have ALLO shares performed this year? Allogene Therapeutics' stock was trading at $3.21 at the start of the year. Since then, ALLO shares have decreased by 24.9% and is now trading at $2.41. View the best growth stocks for 2024 here. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative trailing twelve-month return on equity of 50.24%. What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' top institutional shareholders include Primecap Management Co. CA (2.71%), Perceptive Advisors LLC (1.30%), Dimensional Fund Advisors LP (1.22%) and Lynx1 Capital Management LP (1.07%). Insiders that own company stock include Arie Belldegrun, Veer Bhavnagri, Rafael Amado, Franz B Humer, Owen N Witte, David D Chang, Alison Moore and Eric Thomas Schmidt. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC) and AbbVie (ABBV). This page (NASDAQ:ALLO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
